Spiriva Dosing
For COPD, use Spiriva HandiHaler 18 mcg (one capsule) once daily, and for asthma in patients ≥12 years, use Spiriva Respimat 2.5 mcg (two puffs of 1.25 mcg) once daily. 1
COPD Dosing
Spiriva HandiHaler: 18 mcg once daily
- Administer as two inhalations of one capsule (18 mcg tiotropium) using the HandiHaler device 1
- Timing: Once daily at the same time each day
- Critical: For oral inhalation only—DO NOT swallow the capsules 1
- Use only with the HandiHaler device provided; capsules are not compatible with other devices
The 18 mcg dose was selected based on dose-ranging studies showing comparable bronchodilator response at doses from 9 to 36 mcg, with advantages in the safety profile at doses below 36 mcg 2. This dosing provides sustained 24-hour bronchodilation with once-daily administration, confirmed in trials showing significant improvements in trough FEV1 (measured 20-24 hours post-dose) 2.
Clinical context: The 2023 Canadian Thoracic Society guidelines recommend LAMA therapy (including tiotropium) as part of combination therapy for patients with moderate-to-severe COPD, particularly those with high symptom burden (CAT ≥10, mMRC ≥2) and impaired lung function (FEV1 <80% predicted) 3.
Asthma Dosing
Spiriva Respimat: 2.5 mcg once daily
- Administer as two puffs (1.25 mcg per puff) once daily using the Respimat Soft Mist Inhaler 4
- Approved for patients ≥12 years of age 4
- Add-on therapy to inhaled corticosteroids (ICS) or ICS/long-acting β2-agonist (LABA) combinations
Key dosing distinction: The asthma dose (2.5 mcg) is half the COPD dose (5 mcg Respimat equivalent). Notably, phase II dose-ranging studies demonstrated that the 2.5 mcg dose produced better overall pulmonary function measures than the 5 mcg dose in asthma patients, justifying selection of the lower dose 5. This represents a critical difference from COPD dosing.
The evidence supports tiotropium as add-on therapy for moderate-to-severe asthma inadequately controlled by ICS or ICS/LABA, with demonstrated improvements in lung function and reduction in exacerbations 4.
Device-Specific Considerations
HandiHaler (COPD):
- Dry powder inhaler requiring adequate inspiratory flow
- Single-use capsules must be pierced before inhalation
- Not interchangeable with Respimat device
Respimat (Asthma):
- Soft mist inhaler with slow, prolonged aerosol delivery
- Does not require coordination with inspiration
- Provides consistent dosing across patient populations 6
Special Populations
Renal impairment: Patients with moderate to severe renal impairment should be monitored closely for anticholinergic side effects (dry mouth, constipation, urinary retention) 1. No dose adjustment is specified, but increased vigilance is warranted.
Elderly patients: The incidence of dry mouth, constipation, and urinary tract infections increases with age 1. However, efficacy is maintained across age groups without need for dose adjustment 7.
Common Pitfalls
- Device confusion: Do not use HandiHaler capsules in Respimat device or vice versa—these are completely different formulations and delivery systems
- Swallowing capsules: HandiHaler capsules must be inhaled, not swallowed 1
- Wrong dose for indication: Using 5 mcg for asthma when 2.5 mcg is the approved and more effective dose 5
- Acute use: Tiotropium is not a rescue medication—it is for maintenance therapy only 1
Contraindications and Warnings
- Contraindicated in patients with hypersensitivity to tiotropium, ipratropium, or any components 1
- Use with caution in narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction 1
- Avoid concomitant use with other anticholinergic medications due to additive anticholinergic effects 1
- Monitor for paradoxical bronchospasm—discontinue immediately if this occurs 1